Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826238 | 0.93 | CYP3A4 (0.44) | CYP3A4PSIP1P2RX3HCRTR1HCRTR2 | |
| SCHEMBL15468950 | 0.84 | CYP3A4 (0.39) | CYP3A4PSIP1P2RX3HCRTR1HCRTR2 | |
| SCHEMBL15182563 | 0.83 | PSIP1 (0.39) | CYP3A4PSIP1P2RX3PTGES | |
| SCHEMBL15468858 | 0.83 | CYP3A4 (0.40) | CYP3A4PSIP1HCRTR1HCRTR2 | |
| SCHEMBL15468878 | 0.80 | CYP3A4 (0.38) | CYP3A4PSIP1 | |
| SCHEMBL15468970 | 0.80 | CYP3A4 (0.38) | CYP3A4PSIP1P2RX3 | |
| SCHEMBL15165199 | 0.79 | CYP3A4 (0.36) | CYP3A4PSIP1 | |
| SCHEMBL15468844 | 0.78 | CYP3A4 (0.37) | CYP3A4PSIP1 | |
| SCHEMBL15342158 | 0.78 | CYP3A4 (0.37) | CYP3A4PSIP1 | |
| SCHEMBL15468860 | 0.77 | CYP3A4 (0.35) | CYP3A4PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879023-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9464096-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9006229-B2 | Benzothiazole compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | FURIN, NFATC1, NPC1 | CYP3A4 3708/4885PSIP1 2398/4885P2RX3 4714/4885 |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FURIN, NFATC1, RUNX1 | CYP3A4 940/4885PSIP1 1964/4885P2RX3 3933/4885 |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, NPC1 | CYP3A4 3726/4885PSIP1 2455/4885P2RX3 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.